CytomX Therapeutics (CTMX) Other Accumulated Expenses (2014 - 2026)
CytomX Therapeutics (CTMX) posted Other Accumulated Expenses of $1.1 million for Q1 2026, up 697.89% on a QoQ basis from $142000.0 in Q4 2025, and up 1698.41% year-over-year from $63000.0 in Q1 2025.
CytomX Therapeutics (CTMX) Other Accumulated Expenses (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- Quarterly Other Accumulated Expenses rose 1698.41% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 1698.41% YoY) and the FY2025 annual result came in at $142000.0, down 71.02% from the prior year.
- Other Accumulated Expenses was $1.1 million for Q1 2026 at CytomX Therapeutics, up from $142000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.1 million in Q1 2026 and bottomed at $63000.0 in Q1 2025.
- A 5-year average of $349176.5 and a median of $292000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Other Accumulated Expenses sank 86.15% — and 2026, when it surged 1698.41%.
- CytomX Therapeutics' Other Accumulated Expenses stood at $261000.0 in 2022, then rose by 20.31% to $314000.0 in 2023, then soared by 56.05% to $490000.0 in 2024, then tumbled by 71.02% to $142000.0 in 2025, then surged by 697.89% to $1.1 million in 2026.
- Business Quant data shows CTMX's Other Accumulated Expenses at $1.1 million in Q1 2026, $142000.0 in Q4 2025, and $341000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | 142,000.00 |
| Sep 30, 2025 | 341,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Mar 31, 2025 | 63,000.00 |
| Dec 31, 2024 | 490,000.00 |
| Sep 30, 2024 | 292,000.00 |
| Jun 30, 2024 | 202,000.00 |
| Mar 31, 2024 | 455,000.00 |
| Dec 31, 2023 | 314,000.00 |
| Sep 30, 2023 | 343,000.00 |
| Jun 30, 2023 | 161,000.00 |
| Mar 31, 2023 | 359,000.00 |
| Dec 31, 2022 | 261,000.00 |
| Sep 30, 2022 | 184,000.00 |
| Jun 30, 2022 | 142,000.00 |
| Mar 31, 2022 | 943,000.00 |
| Dec 31, 2021 | 713,000.00 |
| Sep 30, 2021 | 551,000.00 |
| Jun 30, 2021 | 926,000.00 |